COVID-19 and the Functionality of Antivirals: The Day After Tomorrow

Beigel JH , Tomashek KM , Dodd LE , et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020; 383(19):1813-1826.

Spinner CD , Gottlieb RL , Criner GJ , et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020; 324(11):1048-1057.

Gottlieb RL , Vaca CE , Paredes R , et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022; 386(4):305-315.

Jayk Bernal A , Gomes da Silva MM , Musungaie DB , et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021; 386(6):509-520.

Hammond J , Leister-Tebbe H , Gardner A , et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022; 386(15):1397-1408.

Dougan M , Nirula A , Azizad M , et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021; 385(15):1382-1392.

Weinreich DM , Sivapalasingam S , Norton T , et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi:10.1056/NEJMoa2108163

Gupta A , Gonzalez-Rojas Y , Juarez E , et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022; 327(13):1236-1246.

Lomakin N V , Bakirov BA , Protsenko DN , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm Res. 2021; 70(10-12):1233-1246.

Levin MJ , Ustianowski A , De Wit S , et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19. N Engl J Med. April 20, 2022. doi:10.1056/NEJMoa2116620

Group RC , Horby P , Lim WS , et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693-704.

US National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed May 4, 2022. https://www.covid19treatmentguidelines.nih.gov

Rockett R , Basile K , Maddocks S , et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N Engl J Med. 2022; 386(15):1477-1479.

Tao K , Tzou PL , Pond SLK , Ioannidis JPA , Shafer RW . Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Preprint. Preprints. Posted March 10, 2022. Accessed May 20, 2022. doi:10.20944/preprints202203.0155.v1

Tada T , Zhou H , Dcosta BM , et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine. 2022; 78:103944.

Gandhi S , Klein J , Robertson AJ , et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022; 13:1547.

WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022; 399(10339):1941-1953.

Strasfeld L , Chou S . Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010; 24(2):413-437.

Hussain M , Galvin HD , Haw TY , Nutsford AN , Husain M . Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017; 10:121-134.